Acorn Capital Advisors, LLC Candel Therapeutics, Inc. Transaction History
Acorn Capital Advisors, LLC
- $144 Billion
- Q1 2025
A detailed history of Acorn Capital Advisors, LLC transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Acorn Capital Advisors, LLC holds 2,152,252 shares of CADL stock, worth $10.7 Million. This represents 8.46% of its overall portfolio holdings.
Number of Shares
2,152,252
Previous 1,939,644
10.96%
Holding current value
$10.7 Million
Previous $16.8 Billion
27.77%
% of portfolio
8.46%
Previous 8.84%
Shares
4 transactions
Others Institutions Holding CADL
# of Institutions
88Shares Held
15.2MCall Options Held
536KPut Options Held
335K-
Baker Bros. Advisors LP New York, NY2.44MShares$12.1 Million0.16% of portfolio
-
Northpond Ventures, LLC1.94MShares$9.6 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.74MShares$8.61 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA881KShares$4.37 Million0.41% of portfolio
-
Black Rock Inc. New York, NY823KShares$4.08 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $143M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...